

Israel Bendit

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4670127/publications.pdf>

Version: 2024-02-01

90
papers

1,768
citations

394421

19
h-index

302126

39
g-index

93
all docs

93
docs citations

93
times ranked

2477
citing authors

#	ARTICLE	IF	CITATIONS
1	Impact of pregnancy on the outcomes of childbearing age women with chronic myeloid leukemia. <i>American Journal of Hematology</i> , 2022, 97, E72.	4.1	2
2	Adult acute lymphoblastic leukemia in a resource-constrained setting: outcomes after expansion of genetic evaluation. <i>Hematology</i> , 2022, 27, 396-403.	1.5	5
3	Brazilian chronic myeloid leukemia working group recommendations for discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia in clinical practice. <i>Hematology, Transfusion and Cell Therapy</i> , 2022, , .	0.2	0
4	Inclusion of molecular monitoring (BCR-ABL1) in the treatment of chronic myeloid leukemia in the Brazilian Public Health System (SUS): an urgent need for treatment management. <i>Hematology, Transfusion and Cell Therapy</i> , 2021, 43, 50-57.	0.2	3
5	Molecular-Based Score inspired on metabolic signature improves prognostic stratification for myelodysplastic syndrome. <i>Scientific Reports</i> , 2021, 11, 1675.	3.3	2
6	Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis. <i>Leukemia</i> , 2021, 35, 440-453.	7.2	159
7	MR 4log and low levels of NK cells are associated with higher molecular relapse after imatinib discontinuation: Results of a prospective trial. <i>Leukemia Research</i> , 2021, 101, 106516.	0.8	5
8	COVID-19 in chronic myeloid leukemia patients in Latin America. <i>Leukemia and Lymphoma</i> , 2021, 62, 3212-3218.	1.3	6
9	A multicenter comparative acute myeloid leukemia study: can we explain the differences in the outcomes in resource-constrained settings?. <i>Leukemia and Lymphoma</i> , 2021, 62, 147-157.	1.3	6
10	Challenges in Chronic Myeloid Leukemia Management in South America. <i>Current Hematologic Malignancy Reports</i> , 2021, 16, 440-447.	2.3	0
11	Rhoa Mutation Is a Potential Biomarker Associated with Adverse Prognosis and High- Tumor Burden in Patients with Nodal Peripheral Lymphomas with T-Helper Follicular Phenotype (nPTCL-Thf): Data from a Brazilian Retrospective Cohort of Nodal PTCL. <i>Blood</i> , 2021, 138, 4482-4482.	1.4	1
12	Risk factors and incidence of thrombosis in a Brazilian cohort of patients with Philadelphia-negative myeloproliferative neoplasms. <i>Journal of Thrombosis and Thrombolysis</i> , 2020, 49, 667-672.	2.1	9
13	<i>MEG3</i> and <i>MEG8</i> aberrant methylation in an infant with neuroblastoma. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28328.	1.5	2
14	Detection of somatic TP53 mutations and 17p deletions in patients with chronic lymphocytic leukemia: a review of the current methods. <i>Hematology, Transfusion and Cell Therapy</i> , 2020, 42, 261-268.	0.2	6
15	Integrating clinical features with genetic factors enhances survival prediction for adults with acute myeloid leukemia. <i>Blood Advances</i> , 2020, 4, 2339-2350.	5.2	11
16	Co-occurrence of DNMT3A, NPM1, FLT3 mutations identifies a subset of acute myeloid leukemia with adverse prognosis. <i>Blood</i> , 2020, 135, 870-875.	1.4	48
17	Salvage treatment for refractory or relapsed acute myeloid leukemia: a 10-year single-center experience. <i>Clinics</i> , 2020, 75, e1566.	1.5	4
18	Clinical, Laboratory, and Genetic Features of Erdheim-Chester Disease Patients from Two Reference Centers in a Developing Country. <i>Blood</i> , 2020, 136, 22-23.	1.4	0

#	ARTICLE	IF	CITATIONS
19	COVID-19 in Chronic Myeloid Leukemia Patients - Brazilian Experience. <i>Blood</i> , 2020, 136, 48-49.	1.4	0
20	Combining gene mutation with gene expression analysis improves outcome prediction in acute promyelocytic leukemia. <i>Blood</i> , 2019, 134, 951-959.	1.4	21
21	Scientific comment on: "Analysis of imatinib adherence in chronic myeloid leukemia: a retrospective study in a referral hospital in the Brazilian Amazon" Who likes to take medicine forever?. <i>Hematology, Transfusion and Cell Therapy</i> , 2019, 41, 103.	0.2	0
22	Guideline on myeloproliferative neoplasms: Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular. <i>Hematology, Transfusion and Cell Therapy</i> , 2019, 41, 1-73.	0.2	3
23	Standardisation and consensus guidelines for minimal residual disease assessment in Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL) by real-time quantitative reverse transcriptase PCR of e1a2 BCR-ABL1. <i>Leukemia</i> , 2019, 33, 1910-1922.	7.2	54
24	Prognostic impact of MYD88 mutation, proliferative index and cell origin in diffuse large B cell lymphoma. <i>Hematology, Transfusion and Cell Therapy</i> , 2019, 41, 50-56.	0.2	2
25	Real-life Outcomes on Acute Promyelocytic Leukemia in Brazil " Early Deaths Are Still a Problem. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e116-e122.	0.4	20
26	Financial Impact of Imatinib Discontinuation in Brazil - a Pharmoeconomic Study. <i>Blood</i> , 2019, 134, 5844-5844.	1.4	2
27	Efficacy and Safety of Generic Imatinib Compared to Glivec in Chronic Phase - Chronic Myeloid Leukemia - a Multicenter, Observational Study. <i>Blood</i> , 2018, 132, 46-46.	1.4	4
28	WHO-2016 Classification in ALL By Cytogenetics, FISH and Molecular Biology - Experience of Two Reference Centers in Brazil. <i>Blood</i> , 2018, 132, 5288-5288.	1.4	0
29	Impact of Treatment Free Remission (TFR) with Nilotinib in 2nd Line for Chronic Myeloid Leukemia on Savings That May Fund All BCR-ABL Tests in the Brazilian Public Healthcare System during and after Nilotinib Treatment. <i>Blood</i> , 2018, 132, 4760-4760.	1.4	1
30	Myeloid Differentiation Factor 88 (MYD88) Gene Mutation in Diffuse Large B-Cell Lymphomas: Should it be Included in Routine?. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, S375.	0.4	0
31	Sustained deep molecular responses in patients switched to nilotinib due to persistent BCR-ABL1 on imatinib: final ENESTcmr randomized trial results. <i>Leukemia</i> , 2017, 31, 2529-2531.	7.2	41
32	Development and evaluation of a secondary reference panel for BCR-ABL1 quantification on the International Scale. <i>Leukemia</i> , 2016, 30, 1844-1852.	7.2	51
33	BLM germline and somatic PKMYT1 and AHCY mutations: Genetic variations beyond MYCN and prognosis in neuroblastoma. <i>Medical Hypotheses</i> , 2016, 97, 22-25.	1.5	10
34	Switching to nilotinib versus imatinib dose escalation in patients with chronic myeloid leukaemia in chronic phase with suboptimal response to imatinib (LASOR): a randomised, open-label trial. <i>Lancet Haematology</i> , 2016, 3, e581-e591.	4.6	34
35	Comparative study of different methodologies to detect the JAK2 V617F mutation in chronic BCR-ABL1 negative myeloproliferative neoplasms. <i>Practical Laboratory Medicine</i> , 2016, 4, 30-37.	1.3	16
36	BCR-ABL Mutations in Chronic Myeloid Leukemia Treated With Tyrosine Kinase Inhibitors and Impact on Survival. <i>Cancer Investigation</i> , 2015, 33, 451-458.	1.3	15

#	ARTICLE	IF	CITATIONS
37	Molecular responses at 3 and 6 months after switching to a second-generation tyrosine kinase inhibitor are complementary and predictive of long-term outcomes in patients with chronic myeloid leukemia who fail imatinib. <i>Leukemia and Lymphoma</i> , 2015, 56, 1787-1792.	1.3	10
38	Dynamic expression of desmin, α -SMA and TGF- β 1 during hepatic fibrogenesis induced by selective bile duct ligation in young rats. <i>Brazilian Journal of Medical and Biological Research</i> , 2014, 47, 850-857.	1.5	15
39	Effect of continued imatinib (IM) in pts with detectable BCR-ABL after \geq 2 years on study on deep molecular responses (MR): 36-month update from ENESTcmr.. <i>Journal of Clinical Oncology</i> , 2014, 32, 7025-7025.	1.6	1
40	Investigation of human parvovirus B19 occurrence and genetic variability in different leukaemia entities. <i>Clinical Microbiology and Infection</i> , 2013, 19, E31-E43.	6.0	21
41	Establishment and Validation of Analytical Reference Panels for the Standardization of Quantitative BCR-ABL1 Measurements on the International Scale. <i>Clinical Chemistry</i> , 2013, 59, 938-948.	3.2	46
42	The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts. <i>Blood</i> , 2013, 121, 4439-4442.	1.4	546
43	Determination of serum levels of imatinib mesylate in patients with chronic myeloid leukemia: validation and application of a new analytical method to monitor treatment compliance. <i>Revista Brasileira De Hematologia E Hemoterapia</i> , 2013, 35, 103-8.	0.7	22
44	Non-neoplastic bulky mediastinal mass presentation in an adolescent patient: a case report. <i>Journal of Medical Case Reports</i> , 2013, 7, 233.	0.8	4
45	Quantification of imatinib in human serum: validation of a high-performance liquid chromatography-mass spectrometry method for therapeutic drug monitoring and pharmacokinetic assays. <i>Drug Design, Development and Therapy</i> , 2013, 7, 699.	4.3	16
46	Primary Myelofibrosis Brazilian Patient Journey: From Initial Symptoms To Treatment. <i>Blood</i> , 2013, 122, 5255-5255.	1.4	1
47	Dasatinib Overrides Imatinib Resistance Mediated by the F359I Residue Mutation in Two Patients with Chronic Myeloid Leukemia. <i>Acta Haematologica</i> , 2012, 127, 56-59.	1.4	1
48	Simultaneous Occurrence of Biphenotypic T Cell/Myeloid Lesions Involving t(12;13)(p13;q14) in a Pediatric Patient. <i>Acta Haematologica</i> , 2012, 127, 165-169.	1.4	4
49	Evaluation of Long-Term Outcomes, Cytogenetic and Molecular Responses with Imatinib Mesylate in Early and Late Chronic-Phase Chronic Myeloid Leukemia: A Report from a Single Institute. <i>Acta Haematologica</i> , 2012, 128, 223-232.	1.4	8
50	Effects of selective bile duct ligation on liver parenchyma in young animals: histologic and molecular evaluations. <i>Journal of Pediatric Surgery</i> , 2012, 47, 513-522.	1.6	14
51	Pretherapeutic Expression of the α -H2A Gene Predicts a Complete Molecular Response to Imatinib Mesylate in Chronic-Phase Chronic Myeloid Leukemia. <i>Acta Haematologica</i> , 2012, 127, 228-234.	1.4	23
52	Chronic myeloid leukemia treatment guidelines: Brazilian Association of Hematology, Hemotherapy and Cell Therapy. <i>Brazilian Medical Association Guidelines Project - 2012. Revista Brasileira De Hematologia E Hemoterapia</i> , 2012, 34, 367-382.	0.7	7
53	Monitoring of BCR-ABL levels in chronic myeloid leukemia patients treated with imatinib in the chronic phase. <i>Revista Brasileira De Hematologia E Hemoterapia</i> , 2011, 33, 211-215.	0.7	14
54	Prognostic impact of α -MYCN, DDX1, TrkA, and TrkC gene transcripts expression in neuroblastoma. <i>Pediatric Blood and Cancer</i> , 2011, 56, 749-756.	1.5	8

#	ARTICLE	IF	CITATIONS
55	International Standardization of Minimal Residual Disease Assessment for in Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL) Expressing m-BCR-ABL Transcripts: Updated Results of Quality Control Procedures by the EWALL and ESG-MRD-ALL Consortia. <i>Blood</i> , 2011, 118, 2535-2535.	1.4	4
56	Clonal Dasatinib Large Granular Expansion Is Associated with Suboptimal and Optimal Leukemia Net Response Criteria in Chronic Myelogenous Leukemia. <i>Blood</i> , 2011, 118, 1696-1696.	1.4	0
57	Current patient management of chronic myeloid leukemia in Latin America. <i>Cancer</i> , 2010, 116, 4991-5000.	4.1	23
58	Molecular measurement of BCR-ABL transcript variations in chronic myeloid leukemia patients in cytogenetic remission. <i>BMC Hematology</i> , 2010, 10, 7.	2.6	6
59	Efficacy and Tolerability after Unusually Low Doses of Dasatinib in Chronic Myeloid Leukemia Patients Intolerant to Standard-Dose Dasatinib Therapy. <i>Clinical Medicine Insights: Oncology</i> , 2010, 4, CMO.S6413.	1.3	7
60	Early Detection of t(8;21) Chromosomal Translocations during Treatment of <i>PML-RARA</i> Positive Acute Promyelocytic Leukemia: A Case Study. <i>Clinical Medicine Insights: Oncology</i> , 2010, 4, CMO.S6446.	1.3	3
61	Response to Dasatinib in a Patient with Concomitant Chronic Myeloid Leukemia and Chronic Lymphocytic Leukemia. <i>Acta Haematologica</i> , 2010, 124, 105-109.	1.4	16
62	Successful Pregnancy and Delivery in a Patient with Chronic Myeloid Leukemia while on Dasatinib Therapy. <i>Advances in Hematology</i> , 2010, 2010, 1-4.	1.0	42
63	Achievement of complete donor-type chimerism and remission with dasatinib in Philadelphia chromosome-positive ALL relapsing after allogeneic transplantation. <i>Bone Marrow Transplantation</i> , 2010, 45, 1125-1126.	2.4	3
64	Efeitos adversos e resposta citogenética em pacientes com leucemia mieloide crônica tratados com imatinibe. <i>Revista Brasileira De Hematologia E Hemoterapia</i> , 2010, 32, 98-98.	0.7	0
65	The performance of semi-quantitative differential PCR is similar to that of real-time PCR for the detection of the MYCN gene in neuroblastomas. <i>Brazilian Journal of Medical and Biological Research</i> , 2009, 42, 791-795.	1.5	8
66	The Use of Imatinib Mesylate as a Lifesaving Treatment of Chronic Myeloid Leukemia Relapse after Bone Marrow Transplantation. <i>Journal of Transplantation</i> , 2009, 2009, 1-4.	0.5	2
67	Emergence of abnormal clone with monosomy 7 in Philadelphia negative cells of CML patients treated with tyrosine kinase inhibitors. <i>International Journal of Hematology</i> , 2009, 89, 123-125.	1.6	10
68	Two successful pregnancies in a woman with chronic myeloid leukemia exposed to nilotinib during the first trimester of her second pregnancy: case study. <i>Journal of Hematology and Oncology</i> , 2009, 2, 42.	17.0	69
69	Simultaneous detection of JAK2 V617F mutation and Bcr-Abl translocation in a patient with chronic myelogenous leukemia. <i>International Journal of Hematology</i> , 2008, 88, 243-245.	1.6	28
70	Complete response to imatinib mesylate treatment in a 12-month-old patient with chronic myeloid leukemia. <i>Pediatric Blood and Cancer</i> , 2008, 50, 1078-1078.	1.5	2
71	Studies of RET gene expression and acetylcholinesterase activity in a series of sporadic Hirschsprung's disease. <i>Pediatric Surgery International</i> , 2008, 24, 1017-1021.	1.4	3
72	Avaliação do percentual de compatibilidade HLA entre membros da mesma família para pacientes à espera de transplante de medula óssea em Santa Catarina, Brasil. <i>Revista Brasileira De Hematologia E Hemoterapia</i> , 2008, 30, .	0.7	3

#	ARTICLE	IF	CITATIONS
73	Expression Profile Analysis of Genes Related to Resistance/Sensibility to Prednisolone, Daunorubicin, L-Asparaginase and Vincristine in Childhood Acute Lymphoblastic Leukemia.. Blood, 2007, 110, 3463-3463.	1.4	8
74	Cytokeratin 19 Expression by Reverse Transcriptase-Polymerase Chain Reaction in the Peripheral Blood of Prostate Cancer Patients. Tumori, 2005, 91, 248-252.	1.1	6
75	Ethnic Differences in Cerebral Venous Thrombosis. Cerebrovascular Diseases, 2005, 19, 147-151.	1.7	14
76	Mdm2 mRNA expression in salivary gland tumour cell lines. Journal of Oral Pathology and Medicine, 2004, 33, 96-101.	2.7	12
77	Systemic chemotherapy induces microsatellite instability in the peripheral blood mononuclear cells of breast cancer patients. Breast Cancer Research, 2004, 7, R28-32.	5.0	22
78	Peripheral Blood c-erbB-2 Expression by Reverse Transcriptase-Polymerase Chain Reaction in Breast Cancer Patients Receiving Chemotherapy. Clinical Breast Cancer, 2002, 3, 201-205.	2.4	14
79	Growth Hormone and Insulin-like Growth Factor I Axis and Growth of Children With Different Sickle Cell Anemia Haplotypes. The American Journal of Pediatric Hematology/oncology, 2001, 23, 357-363.	1.3	19
80	Deletion of the factor IX gene as a result of translocation t(X;1) in a girl affected by haemophilia B. British Journal of Haematology, 2001, 113, 616-620.	2.5	10
81	CK-19 Expression by RT-PCR in the Peripheral Blood of Breast Cancer Patients Correlates with Response to Chemotherapy. Breast Cancer Research and Treatment, 2001, 66, 249-254.	2.5	19
82	Interferon-alpha therapy increases type I insulin-like growth factor receptors expression on lymphoid cells from patients with chronic myelogenous leukemia. Leukemia Research, 2001, 25, 711-717.	0.8	10
83	Mutational analysis of N-RAS and GAP-related domain of the neurofibromatosis type 1 gene in chronic myelogenous leukemia. Leukemia Research, 1998, 22, 1003-1007.	0.8	8
84	Concomitant p53 mutation and MYCN amplification in neuroblastoma. , 1997, 29, 206-207.		14
85	Molecular and immunohistochemical analysis of P53 in pheochromocytoma. British Journal of Cancer, 1995, 72, 1211-1213.	6.4	27
86	Further evidence for the lack of correlation between the breakpoint site within M-BCR and CML prognosis and for the occasional involvement of p53 in transformation. Cancer Genetics and Cytogenetics, 1995, 84, 105-112.	1.0	11
87	N-myc Oncogene Expression in Porcine Renal Development and Oncogenesis. Pediatric Research, 1991, 29, 268-271.	2.3	6
88	N-myc oncogene expression and amplification in metastatic lesions of stage IV-S neuroblastoma. Cancer, 1990, 65, 2572-2575.	4.1	22
89	Molecular phenotype of a pediatric small round cell tumor. Cancer, 1990, 66, 1534-1538.	4.1	2
90	Monitora�o molecular da Leucemia Miel�ide Cr�nica na era do imatinibe. Revista Brasileira De Hematologia E Hemoterapia, 0, 30, .	0.7	0